Year in Review
In a year of unprecedented hardship we witnessed never-before-seen speeds of innovation and levels of collaboration in the global healthcare community.
As we reflect on the past year, we are proud to share highlights from our team and portfolio who responded, contributed, and innovated throughout it all.
New Companies Joined Our Portfolio
Including incubation and launch of 3 startups
Artis COVID-19 Response Timeline
IDbyDNA is an early responder to adapt its infectious disease diagnostic platform to detect SARS-CoV-2
In response to the pandemic, the ARTIS team starts weekly trackers of healthcare innovation across treatments, vaccines and diagnostics. Over six months, the tracker was featured in publications including Visual Capitalist and Zero Hedge, translated to Spanish in Sociedad Ecuatoriana De Microbiología, and shared on social channels globally.
Public Health + Tech
Palantir partners with leading health institutions (e.g., NHS, CDC, the VA) to help in contact tracing, predicting outbreaks, and monitoring supply needs.
Emergency Use Authorization (EUA)
The FDA issues EUA for Eko's ECG-based Low Ejection Fraction screening algorithm, designed to improve detection of heart failure during the COVID-19 pandemic.
Excision is recognized for developing CRISPR-based therapeutics for infectious diseases with the potential to apply its gene editing platform to target COVID-19.
Respiratory Panel Launch
IDbyDNA and Illumina co-launch their Respiratory Pathogen ID/AMR Target Enrichment Panel, capable of testing nearly 300 pathogens in a single test, and distinguishing if someone is infected with COVID-19, the flu or another respiratory disease.
Nearly 30 of our Pioneers gathered for our Pioneer Day, sharing different ways they were involved in COVID-19, our Portfolio Companies, and other innovative healthcare initiatives.
ARTIS co-sponsored Second Front's Offset Symposium alongside the Defense Entrepreneurs Forum and the Defense Innovation Unit, with this year's theme focused on Biosecurity in light of the pandemic.
Paul Garofolo, CEO of Locus Biosciences, also spoke on Reactive Biosecurity: Counter-measures, Vaccines & Therapeutics.
Second Front Systems hosts symposium on Biosecurity.
Telemedicine has been around for the past couple of decades, but it's been limited in its use and reimbursement. With COVID, Medicare / Medicaid is now paying for any virtual care delivered to patients, and we're seeing all the major insurance carriers start to shift and pay for telemedicine. This change in telemedicine and reimbursement is a once in a hundred year change in healthcare.
For decades, therapeutic development efforts have failed to cure viral infectious diseases such as HIV or Hepatitis B. Now with technologies like CRISPR, expanded genetic sequencing databases, advances in software and analytics, increased understanding of gene therapy activity in commercial settings, and demonstrated proof-of-concept of cures in animals, we are positioned to progress therapeutics to potentially cure these devastating diseases.
In our modern society we manufacture almost everything through chemical processes, whether it's the food that we eat or the drugs that we take. Imagine big plants, high temperatures, high pressures. Manufacturing hasn’t had a renaissance. Enzyme engineering is the way to get there and deep learning makes the perfect platform.
In many ways our understanding of human biology, particularly in the role of certain drivers of cancer, has outstripped our chemistry capabilities. A lot of the high-hanging fruit in drug discovery has been called ‘undruggable,’ and we’re working to change that. AI and drug discovery takes more than computer science and biology. Don’t forget the chemistry.
2020 and the COVID-19 pandemic have shone a light on the importance of continued innovation in infectious diseases. We are facing a rising tsunami of antibiotic resistant infections that will hit our healthcare system because of the historical misuse and overuse of antibiotics, particularly during this pandemic. At Locus, our crPhage™ products, CRISPR-Cas3 enhanced bacteriophage, are designed to meet this challenge head-on and much more. We truly believe that this new modality could change the face of medicine.
FORMER ACTING ADMINISTRATOR AT CMS
We are experiencing historic changes in the delivery of health care due to COVID, many of which will continue into 2021. Long standing beliefs have changed: services can be delivered via telehealth — outside the walls of hospitals and nursing homes, innovation can happen more quickly without risking patient lives, and health disparities matter. Our journey is not over and 2021 will continue to create new opportunities for change.
FORMER CEO AT PFIZER AND OPERATING PARTNER AT ARTIS
COVID-19 has accelerated trends toward consumer-controlled delivery of care and personalized health information. Consumers will continue to manage more substantial amounts of their health care through personalized technology (at home and on the move) that they control. This will reduce the role and costs from intermediaries and speed up the efficiency of health care delivery.
CHIEF DIVERSITY OFFICER
2020 showed us that the fight for health equity is a movement, not a moment. In 2021, we need to prioritize success in reaching underserved populations in clinical research. We all must step up and speak up to help build a more equitable system.
VP COLLEAGUE EXPERIENCE
In 2021 we will see dramatic change in the way we work. We will evolve into a more flexible, fit for purpose work arrangement, where people are more intentional in where and how they connect to get work done. The traditional 9-5 will transition into a blend of in-office collaboration and remote-focused work time. Offices themselves will start to transition into collaboration spaces rather than “office space.”
2021 will be a turning point. Supply chain questions have moved to center stage and will open new exciting possibilities for tech development and entrepreneurship. However, to really address healthcare and sustainability concerns, we must apply solutions to central questions regarding societal disparities, healthcare access, and the undeniable need for consistent dissemination of reliable scientific information.
FORMER EXECUTIVE DIRECTOR, EMA
The ongoing pandemic has had a huge impact on the way we develop new medicines. We have been forced to conduct R&D and clinical trials in a different way. Relying on digital tech and remote communication to run trials & regulatory procedures enabled us to approve a new vaccine in record time. In 2021 many of these new processes will be the "new normal," accelerating drug approvals in a more cost-effective way.
European Medicines Agency
Wishing you a happy and healthy holiday season and new year from the ARTIS team
©2021 Artis Ventures. All rights reserved.